Generic products reduce the costs of HIV treatment. Few generic second-line antiretroviral products are available. We assessed pharmacokinetics, safety and efficacy of generic lopinavir/ritonavir (LPV/r) produced by the Government Pharmaceutical Organization (GPO) of Thailand in Thai HIV-infected adults.
Methods
This was a single-arm prospective study. Patients with plasma HIV-1 RNA<50 copies/ml for ≥24 weeks, who were protease inhibitor (PI)-naive or experienced, were eligible. Patients started generic LPV/r tablets, 400/100 mg twice daily. At week 4, therapeutic drug monitoring was performed and analysed by validated HPLC. In patients using Kaletra® (Abbott Laboratories, North Chicago, IL, USA) soft gel capsules (SGC) or generic LPV/r tablets produced by Mylan (Canonsburg, PA, USA; formerly Matrix, Hyderabad, India) prior to study entry, we compared the plasma minimum concentrations (Cmin) of the different formulations. Plasma HIV-1 RNA and safety were assessed until week 48.
Results
A total of 70 patients (32 males) were enrolled. Mean (sd) age was 40.7 (7.9) years and mean (sd) body weight was 60.3 (9.0) kg. Before study entry, all patients were virologically suppressed using a PI-based regimen; 62 (88.6%) were using LPV/r (Kaletra® SGC n=22 and Mylan generic tablets n=40). Mean (sd) Cmin of GPO lopinavir and GPO ritonavir at week 4 were 7.1 (2.9) mg/l and 0.39 (0.21) mg/l, respectively, and not significantly different from the Cmin when taking Kaletra® SGC or Mylan generic tablets. After 48 weeks, 95.6% of patients maintained plasma HIV-1 RNA<50 copies/ml. Four grade 3 and no grade 4 adverse events were reported.
Conclusions
Generic LPV/r showed adequate levels, good tolerability and excellent 48-week efficacy.
References
1.
ShamH.L., KempfD.J., MollaA.ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother1998; 42: 3218–3224.
2.
World Health Organization.Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. 2010 revision. (Accessed 15 January 2012.) Available from www.who.int/hiv/pub/arv/adult2010/en/index.html.
3.
BensonC.A., DeeksS.G., BrunS.C.Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis2002; 185: 599–607.
4.
HicksC.B., CahnP., CooperD.A.Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet2006; 368: 466–475.
5.
KleinC.E., ChiuY.L., AwniW.The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr2007; 44: 401–410.
6.
CawthorneP., FordN., LimpananontJ., TienudomN., PurahongW.WHO must defend patients’ interests, not industry. Lancet2007; 369: 974–975.
7.
van der LugtJ., LangeJ., AvihingsanonA.Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals. Antivir Ther2009; 14: 1001–1004.
8.
DrosteJ.A., Verweij-Van WissenC.P., BurgerD.M.Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit2003; 25: 393–399.
9.
Médecins Sans Frontières. Untangling the web of antiretroviral price reduction. Lopinavir/ritonavir.2011. (Accessed 17 January 2012.) Available from utw.msfaccess.org/drugs/4fe29e91850dfc2ba8000019.
